MedPath

Comparison of the safety and efficacy of the combination of Wharton's jelly mesenchymal stem cells conditioned medium and platelet-rich plasma and liposomal of Wharton's jelly mesenchymal stem cells conditioned medium and platelet-rich plasma in the treatment of androgenetic alopecia

Phase 1
Recruiting
Conditions
Androgenetic alopecia.
Androgenic alopecia, unspecified
L64.9
Registration Number
IRCT20200127046282N24
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not using topical or oral medication for the treatment of alopecia during the last six months
AGA type 2-4

Exclusion Criteria

Age under18 years
pregnancy
breastfeeding
History of malignant diseases
Taking any topical or systemic treatment during the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hair density. Timepoint: Before starting the treatment, the end of the first, second, third month and one month after the end of the treatment period (end of the fourth month). Method of measurement: Biometric examination will be done and the findings from VISIOFACE and TES-TB (hair loss type with X1 lens, hair density and scalp condition with X60Triple lens, hair diameter and PORE condition with KPL X150 lens and hair shaft surface condition with X700 lens) It will be recorded for each patient.
Secondary Outcome Measures
NameTimeMethod
Side effects. Timepoint: One week after session. Method of measurement: Questionnaire and visit.;Satisfaction. Timepoint: One months after the last session. Method of measurement: Satisfaction Questionnaire and visit.;Tolerability. Timepoint: Each session after transplantation. Method of measurement: Questionnaire and visit.
© Copyright 2025. All Rights Reserved by MedPath